Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
ConditionDiffuse Large B-Cell Lymphoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Adult aged 18 years or older.
Histologically confirmed diagnosis of R/R DLBCL with plan for CAR T or BsAb therapy at Yale New Haven Hospital.
Disqualifiers
Participants who are pregnant or currently breastfeeding.
Participants with history of prior radiation exposure for research purposes within the past year, such that participation in this study would place them over the FDA limits for annual radiation exposure.
Participants who are unable to safely receive FDG PET tracer.
Any condition that would, in the investigator's judgment, interfere with full participation in the study and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.
Trial design
Treatments tested in this trial
- Bridging Radiation Therapy
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
American Cancer Society, Inc.
Collaborator
Source ClinicalTrials.gov